CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Protagonist Therapeutics Inc - PTGX CFD

36.75
0.71%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Tue - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.14
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023346 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001124 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 36.49
Open 36.75
1-Year Change 49.57%
Day's Range 36.4 - 37.19
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 17, 2025 36.75 0.22 0.60% 36.53 37.20 36.29
Jan 16, 2025 36.49 -0.86 -2.30% 37.35 37.36 34.98
Jan 15, 2025 37.87 0.57 1.53% 37.30 39.92 37.30
Jan 14, 2025 36.60 0.19 0.52% 36.41 37.03 36.39
Jan 13, 2025 37.06 1.06 2.94% 36.00 37.09 35.31
Jan 10, 2025 36.56 -0.24 -0.65% 36.80 37.36 36.25
Jan 8, 2025 37.57 -0.83 -2.16% 38.40 38.70 36.86
Jan 7, 2025 38.38 0.40 1.05% 37.98 39.06 37.95
Jan 6, 2025 38.04 -0.23 -0.60% 38.27 39.71 37.49
Jan 3, 2025 39.48 1.39 3.65% 38.09 39.93 38.09
Jan 2, 2025 38.87 0.16 0.41% 38.71 39.45 38.41
Dec 31, 2024 38.52 0.07 0.18% 38.45 39.09 38.08
Dec 30, 2024 38.46 0.35 0.92% 38.11 38.72 37.95
Dec 27, 2024 38.89 0.15 0.39% 38.74 39.55 38.40
Dec 26, 2024 39.42 1.06 2.76% 38.36 39.61 38.36
Dec 24, 2024 39.18 0.44 1.14% 38.74 39.95 38.74
Dec 23, 2024 40.52 0.18 0.45% 40.34 41.14 39.55
Dec 20, 2024 41.21 2.35 6.05% 38.86 41.60 38.85
Dec 19, 2024 39.49 0.67 1.73% 38.82 39.88 38.82
Dec 18, 2024 38.97 -1.08 -2.70% 40.05 41.02 38.55

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Protagonist Therapeutics, Inc. Company profile

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Protagonist Therapeutics Inc revenues decreased 4% to $27.4M. Net loss increased 90% to $125.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 66% to $117M (expense), General and administrative - Balancin increase of 33% to $19.8M (expense).

Industry: Biotechnology & Medical Research (NEC)

7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US

People also watch

Gold

2,703.08 Price
-0.430% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0138%
Overnight fee time 22:00 (UTC)
Spread 0.60

XRP/USD

3.20 Price
-2.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01598

BTC/USD

102,773.35 Price
+3.420% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

3,356.42 Price
+1.900% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading